A robust network of transcription factors and an open chromatin landscape are hallmarks of the naive pluripotent state. Recently, the acetyllysine reader Brd4 has been implicated in stem cell maintenance, but the relative contribution of Brd4 to pluripotency remains unclear. Here, we show that Brd4 is dispensable for self-renewal and pluripotency of embryonic stem cells (ESCs). When maintained in their ground state, ESCs retain transcription factor binding and chromatin accessibility independent of Brd4 function or expression. In metastable ESCs, Brd4 independence can be achieved by increased expression of pluripotency transcription factors, including STAT3, Nanog or Klf4, so long as the DNA methylcytosine oxidases Tet1 and Tet2 are present. These data reveal that Brd4 is not essential for ESC self-renewal. Rather, the levels of pluripotency transcription factor abundance and Tet1/2 function determine the extent to which bromodomain recognition of protein acetylation contributes to the maintenance of gene expression and cell identity.
T he interplay between transcription factors and the chromatin landscape is a critical determinant of lineage-specific gene expression programmes that define cell identity. In embryonic stem cells (ESCs), a network of transcription factors, including Oct4, Sox2 and Nanog, contributes to self-renewal and pluripotency 1, 2 . The ability of transcription factors to control gene expression can be amplified or repressed by histone and DNA modifications; in turn, transcription factors influence the expression and localization of chromatin-modifying proteins 3, 4 . Repressive chromatin modifications, such as methylation of DNA and certain histone lysine residues, have been reported to occlude transcription factor binding and block the ability of transcription factors to maintain transcriptional networks [5] [6] [7] . By contrast, histone acetylation can promote the recruitment of transcription factors and bromodomain-containing proteins that are required for pluripotency 8,9 . Mouse ESCs cultured in conventional medium containing serum and leukaemia inhibitory factor (LIF; hereafter S/L) exhibit heterogeneous expression of pluripotency-associated transcription factors and levels of DNA methylation comparable to that observed in somatic cells. The addition of kinase inhibitors against MAP-kinase kinase (MEK) and glycogen synthase kinase 3β (GSK-3β ; '2i') drives murine ESCs into a naive 'ground state' of pluripotency marked by homogenous expression of pluripotency-associated transcription factors and global DNA hypomethylation 10 . Whereas a fraction of S/L-cultured ESCs can be considered naive 11 , the majority is 'metastable' and prone to spontaneous differentiation. By contrast, 2i-cultured ESCs are homogenously naive and continuously self-renew in culture 10 . Histone and DNA demethylation have been implicated in the establishment of the naive ground state [12] [13] [14] [15] [16] [17] , but the role of acetylation of either histones or transcription factors in maintaining naive pluripotency has been less clear.
Histone acetylation promotes gene expression in cis, by modulating charge-driven nucleosomal contacts, and in trans, by recruiting transcriptional co-activator complexes. Bromodomain and extraterminal (BET) domain-containing proteins, such as Brd4, bind to acetylated histone tails and acetylated transcription factors and recruit complexes, including the Mediator complex, that promote gene transcription 18 . Inhibitors against BET family members inhibit gene expression and proliferation in cancer cells and ESCs 19 . Brd4, in particular, has been reported to be essential for mouse post-implantation development and the culture of ESCs in vitro, suggesting that the reading of acetylation by BET family members is essential for the maintenance of embryonic pluripotency 8, [20] [21] [22] [23] . However, whether Brd4 is essential for the maintenance of the naive pluripotent state remains an open question.
Results
Brd4 is dispensable in naive ground-state ESCs. Acetylation of histone residues such as H3K9 and H3K27 (H3K9ac and H3K27ac, respectively) decorates promoters of active genes and is associated with transcription 24, 25 . Analyses of chromatin immunoprecipitation followed by sequencing (ChIP-seq) data sets of H3K9ac and H3K27ac in metastable ESCs 26 revealed that genes marked by high promoter histone acetylation are enriched for pluripotency-associated gene signatures (Fig. 1a) . We asked whether these marks are modulated in the ground state of pluripotency. As serum is lipid laden, traditional serum-free naive culture conditions (2i/L) impose a substantial burden for de novo lipid biosynthesis. To exclude possible confounding effects of serum on histone acetylation, which competes with lipid biosynthesis for cytosolic acetylcoenzyme A, we compared histone acetylation in ESCs cultured in S/L with or without 2i, as 2i is sufficient to drive many of the epigenetic and metabolic changes characteristic of ground-state pluripotency 14, 27 .
The addition of 2i increased both H3K9ac and H3K27ac levels at key cis-regulatory loci including enhancers and promoters of pluripotency genes (Fig. 1b ), prompting us to examine the role of Brd4 in the ground state of pluripotency. Genome-wide analyses of Brd4 binding confirmed that Brd4 binding correlated with H3K9ac and H3K27ac levels and revealed that 2i increased Brd4 binding to chromatin genome wide ( Fig. 1c and Supplementary Fig. 1a,b ). The genes associated with the largest Brd4 peaks were enriched for pluripotency-associated gene signatures ( Supplementary Fig. 1c ) and included key pluripotency loci, such as the Nanog enhancer and the Pou5f1 promoter ( Fig. 1d ).
Treating ESCs with small-molecule inhibitors of Brd4, such as JQ1, has been reported to block stem cell self-renewal by displacing Brd4 from key stem cell genes and reducing their expression 8, 23 . Consistent with these findings, JQ1 treatment inhibited Brd4 binding to pluripotency genes in cells cultured in either S/L or S/L + 2i ( Fig. 1d) . Surprisingly, whereas S/L-cultured cells ceased proliferation when treated with JQ1 ( Fig. 2a ), S/L + 2i-grown cells were resistant to the antiproliferative effects of JQ1 (Fig. 2b ). Although ESCs cultured in S/L rapidly lost pluripotency in the presence of JQ1, acquiring a flattened morphology marked by increased cell volume, lost reactivity to alkaline phosphatase (AP) and downregulated Nanog expression, 2i-cultured ESCs seemed unaffected by JQ1 treatment (Fig. 2c-f and Supplementary Fig. 2a ). Metastable ESCs exhibited dose-dependent sensitivity to JQ1, but naive ESCs resisted JQ1 treatment across a wide range of doses ( Supplementary Fig. 2b ). Moreover, 2i-cultured ESCs retained proliferation and ESC-like morphology even upon prolonged passage with JQ1 ( Fig. 2g and Supplementary Fig. 2c ). An alternative BET inhibitor, iBET 28 , similarly caused metastable ESCs to arrest and enlarge, whereas naive ESCs remained resistant ( Supplementary Fig. 2d,e ). 2i-induced resistance to BET inhibitors did not require an embryonic cell of origin: pro-B cells reprogrammed to pluripotency maintained proliferation, volume and AP staining when treated with JQ1 ( Fig. 2h and Supplementary Fig. 2f ,g).
Although each inhibitor (CHIR and PD) provided partial resistance to JQ1, the combined effect of both inhibitors (2i) was required for full JQ1 resistance ( Fig. 2g and Supplementary  Fig. 2h -j). The presence of serum did not seem to influence susceptibility to bromodomain inhibition: ESCs cultured in 2i/L were resistant to JQ1 ( Fig. 2g and Supplementary Fig. 2h -j). These results suggest that the ground state of pluripotency, rather than MEK or GSK-3β inhibition individually, induces JQ1 resistance. Naive ESCs, but not metastable ESCs, were capable of giving rise to AP-positive (AP+ ) colonies even in the ongoing presence of JQ1 ( Supplementary Fig. 2k ). To determine whether ESCs remain bona fide pluripotent cells after JQ1 treatment, ESCs exposed to JQ1 were injected into blastocysts to assay for differentiation competence in vivo. After treatment with JQ1, only ESCs cultured in S/L + 2i contributed to live-born chimaeras ( Fig. 2i,j) .
Although BET inhibitors, such as JQ1 and iBET, target the bromodomain of BET family proteins, inhibition of Brd4 drives the majority of the published effects of BET inhibitors 8, 19, 21 . To probe the role of Brd4 specifically, we performed clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9)-mediated editing of Brd4 using single guide RNA (sgRNA) against Brd4 bromodomain 1 (BD1) 29 . Expression of sgRNA against Brd4 severely compromised the number of viable colonies formed in S/L-cultured ESCs but had no effect on colony formation in S/L + 2i-cultured ESCs ( Fig. 3a and Supplementary  Fig. 3a ,b). Just as 2i preserved Nanog expression in response to JQ1 treatment, genetic editing of Brd4 did not alter Nanog expression in S/L + 2i-cultured ESCs ( Supplementary Fig. 3a ). Accordingly, each Brd4-edited clone retained normal morphology and proliferation when cultured in the presence of 2i ( Supplementary Fig. 3c,d ). This resistance to the effect of Brd4 editing required 2i: within 48 h of 2i removal, Brd4-deficient clones exhibited severe growth defects ( Supplementary Fig. 3d ). When seeded at single-cell density, only clones cultured with 2i were able to form AP+ colonies (Fig. 3b ,c). We next manipulated Brd4 expression using inducible short hairpin RNA (shRNA) against Brd4 (Fig. 3d ). Brd4 knockdown recapitulated the effects of BET inhibition, flattening colonies and blocking proliferation of S/L-cultured ESCs while having no obvious effect on the morphology or proliferation of S/L + 2i-cultured ESCs (Fig. 3e ,f). Although Brd4 was absolutely required for the selfrenewal of metastable ESCs, naive ESCs were capable of forming AP+ colonies even in the presence of continuous Brd4 depletion ( Fig. 3g ). Together, these results suggested that ground-state ESCs tolerate pharmacological and genetic inhibition of Brd4.
Naive ESCs maintain transcriptional networks independently of
Brd4 function. The ability of ESCs grown in 2i to maintain pluripotency in the presence of BET inhibitors suggests that these cells are capable of maintaining pluripotency-associated transcription networks independently of BET protein recognition of acetylated lysines. Indeed, although expression of pluripotency transcription factors required Brd4 activity in S/L-cultured ESCs as previously reported 8, 21, 23 , 2i-cultured ESCs maintained high levels of transcription factor expression even in the presence of pharmacological or genetic inhibition of Brd4 activity ( Fig. 4a,b ). To determine how ESCs sustain transcriptional networks without the help of BET protein co-activators, we analysed gene expression in ESCs treated with JQ1 for 72 h. In metastable ESCs, most genes comprising the pluripotency-associated gene network 30 lost Brd4-binding ability and were dramatically downregulated by prolonged exposure to JQ1 ( Fig. 4c and Supplementary Fig. 4a ). By contrast, the level of expression of these genes remained high in naive ESCs regardless of JQ1 treatment ( Fig. 4c ), suggesting that these cells can sustain transcription in the absence of Brd4 bromodomain function.
To assess the activity of pluripotency-associated transcriptional networks, we looked at the expression of genes identified as direct targets of Oct4, Sox2 and Nanog (OSN) 31 . In the absence of Brd4 function, OSN targets were preferentially downregulated in cells cultured in S/L medium ( Supplementary Fig. 4b ). Similarly, genes that were directly bound by pluripotency factors, such as Oct4, Sox2, Nanog, Klf4 and Rex1 (ref. 32 ), were repressed by JQ1 treatment of cells growing in S/L medium ( Supplementary Fig. 4c ). In both cases, the addition of 2i preserved the expression of these gene sets during JQ1 treatment ( Supplementary Fig. 4d,e ). Thus, whereas JQ1 abrogated pluripotency-associated transcription factor binding to key regulatory loci in metastable ESCs, transcription factor binding to these same loci was higher and relatively resistant to JQ1 in naive ESCs (Fig. 4d) . Chromatin accessibility can be used to infer recruitment of transcriptional activators and co-activators to regulatory elements associated with gene expression 33 . The above results suggested that naive ESCs grown in 2i-containing medium might maintain chromatin accessibility independently of Brd4. Consistent with this hypothesis, assay for transposase-accessible chromatin using sequencing (ATAC-seq) analyses revealed that, although JQ1 induced profound loss of chromatin accessibility in ESCs grown in S/L medium, ESCs cultured in medium containing 2i exhibited minimal changes in chromatin accessibility in the presence of JQ1 ( Fig. 4e and Supplementary Fig. 4f ). Over 60% of the ATAC-seq peaks that were lost in S/L-cultured cells as a result of JQ1 treatment and preserved in S/L + 2i-cultured cells were OSN sites ( Fig. 4f ).
In addition to maintaining chromatin accessibility 34 , Brd4 can potentiate gene expression by associating with the Mediator complex that bridges transcription factor binding and RNA polymerase II recruitment to regulatory elements 18, 35 . Displacement of the Med1 subunit of the Mediator complex following JQ1 treatment correlates with loss of gene expression 8, 18 . Consistent with these previous findings, S/L-grown cells exhibited a profound reduction in genome-wide Med1 recruitment when treated with JQ1. By contrast, ESCs grown in S/L + 2i medium retained high genome-wide Med1 recruitment despite JQ1 treatment ( Fig. 4g and Supplementary Fig. 4g ). Although JQ1 reduced both chromatin accessibility and Med1 binding at pluripotency genes in S/L-cultured ESCs, it had no consistent effect on either parameter at these genes in S/L + 2i-cultured ESCs ( Supplementary Fig. 4h ,i).
The above results suggested that persistent Mediator recruitment might sustain Brd4-independent gene expression in S/L + 2i-cul- tured ESCs. In support of this model, genes that were sensitive to JQ1 in metastable cells, but not in naive cells, lost Med1-binding ability under S/L culture conditions but preserved Med1 binding in the presence of 2i (Fig. 4h ). The Mediator complex facilitates transcription by promoting RNA polymerase II carboxy-terminal domain phosphorylation by transcription factor IIH (TFIIH) and the positive elongation factor P-TEFb 36 . To test the contribution of transcriptional activation by these factors, we cultured cells with inhibitors against cyclin-dependent kinase 7 (CDK7) 37 and CDK9 (ref. 38 ), the active subunits of TFIIH and P-TEFb, respectively 39, 40 .
In contrast to Brd4 inhibition, both CDK7 and CDK9 inhibition triggered loss of Nanog expression and impaired proliferation, regardless of the presence of 2i ( Supplementary Fig. 4j,k) .
Pluripotency-associated transcription factors enable resistance to BET inhibitors.
Sites associated with high Med1 binding in S/L + 2i relative to S/L were highly enriched (96%) in known OSNbinding sites ( Fig. 4i ), suggesting that the pluripotency transcription factor network enabled resistance to BET inhibition by promoting Brd4-independent Mediator recruitment. To further examine the
Sall4 Sox2 hypothesis that a strengthened pluripotency network bestows Brd4 independence, we generated ESCs expressing a granulocyte colonystimulating factor (G-CSF)-inducible LIF receptor transgene harbouring a mutation at tyrosine 118 that results in hyperactivation of the Janus kinase (JAK)-signal transducer and activator of transcription 3 (STAT3) signalling pathway ( Supplementary Fig. 5a ) and drives ESCs into the ground state of pluripotency 41 . Induction of STAT3 signalling rendered cells resistant to JQ1: G-CSF-treated ESCs were able to maintain proliferation, cell volume and expression of pluripotency-associated genes even in the presence of JQ1 (Fig. 5a,b and Supplementary Fig. 5b ). These results suggested that direct reinforcement of the pluripotency transcription network might provide JQ1 resistance. Brd4 is recruited to many of the same sites as key pluripotency transcription factors, such as Nanog, Oct4, Sox2, Klf4 and Esrrb 42 ( Supplementary  Fig. 5c ). Brd4-bound sites form three major clusters: Nanog-bound, Oct4/Sox2/Klf4-bound and Esrrb-bound clusters ( Supplementary  Fig. 5d ). Thus, we tested whether increased expression of transcription factors representing distinct clusters might be sufficient to enable resistance to BET inhibition. ESCs with transgenic Nanog expression ( Supplementary Fig. 5e ) maintained proliferation, cell volume and AP reactivity in the presence of either JQ1 or iBET (Fig. 5c,e and Supplementary Fig. 5f ,g). Moreover, Nanog overexpression sustained the expression of pluripotency genes in JQ1treated cells (Fig. 5d) . Similarly, transgenic expression of Klf4, which binds to a different set of Brd4 targets than Nanog ( Supplementary  Fig. 5d,h) , improved cell proliferation, prevented increases in cell volume and blunted decreases in pluripotent gene expression in response to JQ1 treatment (Fig. 5f,g and Supplementary Fig. 5i ). Dual expression of both Nanog and Klf4 further enhanced resistance to JQ1: expression of pluripotency-associated genes was highest in JQ1-treated Nanog + Klf4-expressing cells (Fig. 5i) , and continuous JQ1 had no significant effect on the formation of AP+ colonies in Nanog + Klf4 lines ( Fig. 5h and Supplementary Fig. 5j ). Thus, resistance to BET inhibition correlates with the strength of the pluripotency transcriptional network.
Tet1/2 cooperate with transcription factors to maintain Brd4independent pluripotency. To determine the mechanism through which enhanced transcription factor expression rendered metastable ESCs resistant to BET inhibitors, we performed ATAC-seq on Nanog transgenic cells in the presence and absence of JQ1. At baseline, Nanog overexpression induced chromatin opening at loci associated with key pluripotency genes (Fig. 6a ). Moreover, Nanog overexpression blunted the JQ1-induced loss of chromatin accessibility at these regions (Fig. 6a ). More generally, Nanog overexpression increased accessibility across a wide range of direct targets of OSN pluripotency factors in JQ1-treated cells (Fig. 6b) .
Binding by OSN transcription factors during the transition to the naive ground state of pluripotency is associated with local loss of DNA methylation 43 . Tet1 (ten-eleven translocation 1) and Tet2, which are methylcytosine oxidases that hydroxylate DNA 5-methylcytosine, are reported to contribute to DNA hypomethylation at a subset of regulatory elements in naive ESCs [12] [13] [14] 44 . In addition, during reprogramming, Nanog cooperates with Tet1 and Tet2 to activate the expression of key reprogramming genes 45 . Tet1 binds to 70% of Brd4bound sites 46 ( Supplementary Fig. 6a,b) , and 73.3% of these sites are also bound by OSN factors (P < 2.2 × 10 −16 , Fisher's exact test).
Consequently, we tested whether the ability of transcription factors to maintain gene expression in JQ1-treated cells might involve Tet1/2. As preliminary evidence, we found that genes that were reported to be both bound and activated by Tet1 in mouse ESCs 46 are significantly enriched among genes that were downregulated by JQ1 treatment in S/L-cultured ESCs (Fig. 6c ). However, in 2i-cultured ESCs, the expression of Tet1-target genes was maintained despite JQ1 treatment (Fig. 6c ). Furthermore, treatment of Nanog-overexpressing ESCs with cobalt chloride (CoCl 2 ), which inhibits iron-dependent dioxygenases including Tet1/2, induced a dose-dependent loss of resistance to JQ1 (Fig. 6d ). Conversely, vitamin C, a cofactor that promotes Tet1/2 activity in ESCs 47 , significantly enhanced the ability of Nanog-overexpressing cells, but not control cells, to resist JQ1 treatment ( Fig. 6e and Supplementary Fig. 6c ). These results suggested that transcription factors, in cooperation with Tet1/2 and potentially other iron-dependent demethylases, drive JQ1 resistance.
As both CoCl 2 and vitamin C can affect multiple cellular processes, we generated ESCs with CRISPR-Cas9-derived mutations in both Tet1 and Tet2 ( Supplementary Fig. 7a ). Consistent with previous studies demonstrating that Tet1 and Tet2 are dispensable for pluripotency 48 , Tet1/2 double-mutant ESCs had no obvious defect in chromatin accessibility, Brd4 expression, growth or morphology under basal conditions ( Supplementary Fig. 7b-d) . However, loss of Tet1/2 function clearly sensitized cells to JQ1, indicating that, in the absence of Tet1/2, cells were more dependent on Brd4 to maintain gene expression ( Supplementary Fig. 7e ). We next tested whether Tet enzymes contributed to the BET inhibitor resistance induced by Nanog or 2i. Overexpression of Nanog in Tet1/2 double- mutant ESCs ( Supplementary Fig. 7f ) revealed that Tet1/2 mutation severely compromised the ability of Nanog to maintain proliferation and generate AP+ colonies in the presence of JQ1 (Fig. 7a,b and Supplementary Fig. 7g ). Similarly, 2i-treated ESCs required Tet1 and Tet2 to sustain JQ1 resistance ( Fig. 7c-f ). Both 2i treatment and Nanog overexpression promoted chromatin accessibility at pluripotency genes in JQ1-treated ESCs (Fig. 7g ). Tet1/2 were required for Nanog-induced increases in accessibility at peaks associated with pluripotency genes ( Supplementary Fig. 7h ). Although Nanog expression was sufficient to preserve accessibility at a subset of JQ1-sensitive peaks, this ability was compromised in the absence of Tet1/2 ( Supplementary Fig. 7i ). In particular, a subset of the peaks whose accessibility was lost with JQ1 treatment but preserved by Nanog overexpression required Tet1/2 in order to be maintained by Nanog ( Supplementary Fig. 7i ). Motif analyses revealed that pluripotency-associated motifs are strongly enriched in all clusters, including Tet1/2-dependent sites ( Supplementary  Fig. 7i ). These results suggested that Tet1/2 are required for maintenance of accessibility at a subset of pluripotency-associated transcription factor targets, and loss of Tet1/2 therefore weakens the pluripotency transcriptional network and compromises JQ1 resistance. Indeed, the ability of both Nanog overexpression and 2i treatment to maintain the expression of pluripotency-associated transcription factors during JQ1 treatment was blunted in Tet1/2 double-mutant ESCs (Fig. 7h,i) .
We next asked whether the reported ability 27 of 2i treatment to enhance glutamine-dependent production of α -ketoglutarate, a co-substrate for DNA and histone-modifying enzymes including Tet1/2, contributed to the maintenance of pluripotent gene expression during JQ1 treatment. Culture with low levels of glutamine did not affect Brd4 expression ( Supplementary Fig. 7j ). However, low glutamine levels impaired the ability of 2i to maintain Nanog expression in the presence of JQ1 (Fig. 7j ). Although glutamine withdrawal probably has pleiotropic effects, these data indicate that 2i-induced production of Tet substrates may also contribute to the resistance to BET inhibitors exhibited by naive ESCs.
Discussion
BET inhibitors have gained wide attention for their ability to block proliferation and self-renewal of stem cells and cancer cells. The efficacy of these inhibitors is tied to their ability to inhibit the expression of key stem cell maintenance genes and oncogenic transcription factors, such as Myc 8, 19, 49, 50 . Here, we demonstrate that naive ESCs exhibit inherent resistance to BET inhibition. When grown in 2i-containing medium or provided enhanced JAK-STAT3 signalling, ESCs maintain proliferation, self-renewal and pluripotency in the presence of BET inhibitors. The ability of naive ESCs to maintain Brd4-independent proliferation and self-renewal is mediated by both a strengthened transcription factor network and the Tet1/2 DNA methylcytosine oxidases, which converge to maintain a transcriptionally permissive chromatin environment. Naive ESCs represent a highly optimized transcriptional state; under less-optimized conditions, such as with metastable ESCs, the reading of histone acetylation remains essential to the maintenance of cellular identity.
The present data indicate that the dependency on reading of histone acetylation to consolidate gene networks is most critical when transcription factor binding and chromatin accessibility are limiting. However, the data do not preclude contributions from additional chromatin modifications, transcriptional activators or co-activators to Brd4-independent maintenance of cell identity, and future work may uncover additional proteins that compensate for BET family inhibition. We favour the general view that when transcrip tion factor networks and chromatin methylation states are collectively optimized, the recognition of lysine acetylation by bromodomain-containing proteins has a relatively minor role in modulating gene expression. In support of this model, loss of DNA (cytosine-5)-methyltransferase 3A (DNMT3A) and polycomb repressive complex 2 (PRC2), which deposit repressive DNA methylation and histone H3 lysine 27 trimethylation (H3K27me3), can lead to BET inhibitor resistance in AML cell lines 51 . Similarly, AML cells expressing mutant forms of isocitrate dehydrogenase 2 exhibit hypermethylation and enhanced sensitivity to Brd4 inhibition 52 . Taken together, these data reveal that a combination of transcription factor networks and permissive chromatin modifications can render Brd4 dispensable to the maintenance of cell identity and illustrate that chromatin modification-based transcriptional regulation is context dependent.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41556-018-0086-3.
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Methods Cell culture. Mouse ESC lines (ESC1) were generated from C57BL/6 × 129S4/ SvJae F1 male embryos as previously described 27 . D34 ESCs were previously described 55 . Nanog-green fluorescent protein (GFP) reporter ESCs and induced pluripotent stem cells generated from haematopoietic CD19+ pro-B cells were a gift from R. Jaenisch (Massachusetts Institute of Technology, Cambridge, MA, USA). ESC1 cells were used for all experiments unless otherwise noted. ESCs were maintained on gelatin-coated plates in S/L medium containing Knockout DMEM (Gibco) supplemented with 10% ESC-qualified FBS (Gemini), penicillin/ streptomycin (Life Technologies), 0.1 mM 2-mercaptoethanol, 2 mM l-glutamine (Life Technologies) and 1,000 U ml -1 LIF (Millipore). For culture in 2i (S/L + 2i), S/L medium was supplemented with 2i: 3 µ M CHIR99021 (Stemgent) and 1 µ M PD0325901 (Stemgent). Cells were adapted to S/L + 2i for at least three passages prior to experiments and were maintained in S/L + 2i for no more than nine passages. Serum-free 2i/L consisted of a 1:1 mix of DMEM/F12 (11302-033, Life Technologies) and Neurobasal medium (21103-049, Life Technologies) containing N2 and B27 supplements (17502-048 and 17504-044, respectively, Life Technologies, 1:100 dilutions), 0.1 mM 2-mercaptoethanol, 2 mM l-glutamine, LIF, CHIR99021 at 3 μ M (Stemgent) and PD0325901 at 1 μ M (Stemgent). For glucose and glutamine deprivation experiments, cells were cultured in medium containing a 1/1 mix of glutamine-free and glucose-free DMEM (A14430-01, Invitrogen) and glutamine-free and glucose-free Neurobasal medium (0050128DJ, Invitrogen) including 10% dialysed FBS and all supplements as described above and containing glucose (Sigma) at either 20 mM or 2 mM or glutamine at either 2 mM or 0.2 mM. JQ1 and iBET (Sigma) were dissolved in dimethylsulfoxide (DMSO) and used at indicated doses. CoCl 2 (0.1 M) and vitamin C (50 mg ml -1 ) were dissolved in water and used at indicated doses. The Leukocyte Alkaline Phosphatase Kit (Sigma) was used to stain cells with AP reagent according to the manufacturer's instructions. Images of cells were taken using a Leica microscope.
Generation of ESC lines. Generation of transgenic cell lines. Nanog and Klf4
mouse cDNA were cloned into piggybac (pCAGGS-IRES-Neo, a kind gift from H. Niwa, Institute of Molecular Embryology and Genetics, Kumamoto, Japan) and pEF1a-IRES-GFP (System Biosciences) plasmids. Approximately 5 × 10 6 ESC1 cells cultured in S/L medium were electroporated with piggybac plus transposase (pBase) in 3/1 ratio using Amaxa ESC Nucleofector Kit (VPH-1001, program A-023, Lonza) and plated onto gelatin-coated plates. About 36-48 h after electroporation, the medium was changed to S/L + G418 at 300 µ g ml -1 for at least 2-3 passages. Nanog + Klf4 double-transgenic lines were generated by electroporating Nanog-expressing lines with pEF1a-Klf4-GFP and then sorting the top 10% GFP-positive cells. Hyperactivated STAT3 ESCs were generated in Nanog-GFP ESCs using GY118F chimaeric LIF receptor piggybac plasmid 56 as described above and selected using 200 µ g ml -1 hygromycin for at least three passages.
Generation of Tet1/2-knockout cell lines. Tet1/2 double-mutant ESCs were obtained using CRISPR-Cas9-derived mutation of Tet1 and Tet2. Tet1 and Tet2 guide RNAs (gRNAs; Tet1, 5′ -tggctgctgtcagggagctca-3′ ; Tet2, 5′ -tgaaagtgccaacagatatcc-3′ ) 57 were cloned into px459 v1 (Addgene plasmid number 48139) containing 2A-PURO selection and electroporated (Amaxa, Lonza) into ESCs. After electroporation, cells were plated at clonal density onto feeder mouse embryonic fibroblasts and subjected to puromycin selection (2 µ g ml -1 ) after 36-48 h. Single colonies were picked and tested for loss of Tet1 and Tet2 by western blot analysis, and clones were confirmed by sequencing of PCR amplicons generated using the following primer pairs: Tet1 forward, 5′ -CCTTCCACAGATGGAGGTACAC-3′ , reverse, 5′ -CTGACCGTCTTCATTCGCCT-3′ ; Tet2 forward, 5′ -AAGCAGTTTCAGCTCAAGTCAC-3′ , reverse, 5′ -GCATCCTTCACATTTGCCATTCT-3′ . Sequencing was performed by the CCIB DNA Core Facility at Massachusetts General Hospital (Cambridge, MA, USA).
Generation of Brd4 BD1-mutant cell lines. ESCs harbouring inactivating mutations at BD1 were obtained using CRISPR-Cas9-derived mutation of Brd4. Previously described gRNA sequences targeting Brd4 (ref. 29 ) or a non-genic region on mouse chromosome 8 (ch8) 58 were cloned into the pCas9 (BB)2A-GFP (pX458, Addgene plasmid number 48138), as previously described 59 . See Supplementary Table 1 for gRNA sequences. ESCs were passaged three times over the course of 6 days to adapt to S/L or S/L + 2i medium. Cells (0.4 × 10 6 ) grown under either SL or S/L + 2i conditions were electroporated using Nucleofector 4D (Amaxa, Lonza) with 5 μ g pX458 plasmid encoding Cas9, EGFP and gRNA targeting Brd4 or ch8 (control), or with empty pX458 vector (control). After electroporation, cells were plated on a feeder layer of irradiated mouse embryonic fibroblasts in S/L or S/L + 2i medium. After 48 h, cells were dissociated with Accutase (Invitrogen) and sorted using the BD FACSAria III sorter (BD Biosciences) to enrich for GFP-positive cells. Approximately 10,000 fluorescence-activated cell sorting (FACS)-sorted GFPpositive cells per experimental condition were seeded on 10-cm plates (on feeders) to enable clonal growth. After 7 days, individual clones (~10 per condition) were picked and split for DNA extraction and expanded (on feeders) to make frozen cell stocks as well as whole-cell lysates using RIPA buffer (Sigma). For preparation of lysates, binding to gelatin-coated dishes for 15 min two consecutive times depleted cells of feeders. Biallelic disruption of Brd4 was assessed by western blot. Clones were confirmed by sequencing PCR amplicons generated using the following primers: forward, 5′ -CCAGTAATGGGGGATGGACT-3′ ; reverse, 5′ -CCCTGTCCAGATGGCTACTC-3′ . Amplicons were cloned (Zero Blunt TOPO PCR Cloning Kit, 450031, Thermo Fisher Scientific) and sequenced using the T3 sequencing primer (Eton Biosciences). Sequencing results were confirmed by sending the same PCR amplicons for deep sequencing at the Memorial Sloan Kettering Cancer Center Integrated Genomics Operation core facility.
Generation of inducible Brd4-shRNA ESC lines. Tetracycline-inducible shRNAs linked to GFP were targeted into D34 ESCs by recombinase-mediated cassette exchange, as previously described 60 . See Supplementary Table 1 for shRNA sequences. D34 ESCs harbour (1) a Cre-activatable tet transactivator, CAGs-LSL-rtTA3-IRES-mKate2 (CAGs-LSL-RIK), which enables doxycycline-mediated induction of tetracyclineregulated element-controlled elements and expression of fluorescent mKate2 upon Cre-mediated recombination, and (2) a recombinase-mediated cassette exchange-'homing cassette', which allows for direct single-copy transgenic integration downstream of the collagen type I gene (Col1a1), as previously described 55 . Following hygromycin selection, targeted D34 clones were treated with adenoviral Cre recombinase (University of Iowa) and plated at low density for isolation of individual Cre-recombined clones, as identified by positive mKate2 fluorescence. Ten individual Cre-recombined clones were picked for each different shRNA, and consistent GFP induction was confirmed by fluorescence microscopy upon doxycycline induction (1 μ g m -1 ). Adenoviral Cre-mediated LoxP recombination was also confirmed by genotyping using specific primers (Supplementary Table 2 ).
ChIP. Native ChIP assays (histones) were performed with approximately 6 × 10 6 ESCs per experiment. Cells were subjected to hypotonic lysis and treated with micrococcal nuclease to recover mono-to tri-nucleosomes. Nuclei were lysed by brief sonication and dialysed into N-ChIP buffer (10 mM Tris pH 7.6, 1 mM EDTA, 0.1% SDS, 0.1% sodium deoxycholate and 1% Triton X-100) for 2 h at 4 °C. Soluble material was incubated overnight at 4 °C after the addition of 0.5-1 μ g H3K9ac antibody (9649, Cell Signaling Technologies) or H3K27 antibody (39133, Active Motif) bound to 25 μ l protein A Dynal magnetic beads (Invitrogen), with 5% kept as input DNA. Magnetic beads were washed, chromatin was eluted and ChIP DNA was dissolved in 10 mM Tris pH 8 for quantitative PCR (qPCR) reactions (see Supplementary Table 3 for primer pairs). Three independent ChIP experiments were performed. The data shown are averaged qRT-PCR values of technical replicates (n = 3) from one representative immunoprecipitation.
Brd4, Nanog and Med1 ChIP was carried out as previously described 43, 61 . ESCs (1 × 10 7 ) treated with DMSO or 500 nM JQ1 for 24 h were used per immunoprecipitation. Cells were chemically crosslinked by the addition of formaldehyde (final concentration, 1%) for 10 min at room temperature. After quenching with glycine, cells were rinsed twice with PBS, flash frozen in liquid nitrogen and stored at − 80 °C before use.
For Med1 and Nanog immunoprecipitation, cells were resuspended in 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 0.1% SDS and 1% Triton X-100 and sonicated for approximately 8 min using a Covaris E220 ultrasonicator. The resulting whole-cell extract was centrifuged and the supernatant was incubated for 1 h at 4 °C with 50 μ l protein G magnetic beads that had been pre-incubated with 5 μ g of control rabbit IgG. The supernatant was then incubated overnight at 4 °C with 50 μ l protein G magnetic beads that had been pre-incubated with an anti-Med1 antibody (Bethyl Laboratories) or anti-Nanog antibody (Cosmo Bio). Beads were then washed once with sonication buffer, once with 20 mM Tris (pH 8.0), 500 mM NaCl, 2 mM EDTA, 0.1% SDS, 1% Triton-X100, once with 10 mM Tris, 250 mM lithium chloride, 2 mM EDTA, 1% NP-40 and once with Tris-EDTA buffer (TE) containing 10 mM Tris-HCl, pH 8.0, 1 mM EDTA and 50 mM NaCl. Bound complexes were eluted from the beads in 10 mM Tris, 1% SDS and 10 mM EDTA by heating at 65 °C for 30 min with continuous shaking. Crosslinking was reversed by overnight incubation at 65 °C. Input DNA from the sonication step was also treated for crosslink reversal.
For Brd4 immunoprecipitation, cells were resuspended in 50 mM Tris (pH 8.0), 10 mM EDTA and 1% SDS and sonicated for approximately 12 min using a Diagenode Bioruptor. The resulting whole-cell extract was centrifuged and the supernatant was immediately diluted with four volumes of ChIP dilution buffer (20 mM Tris pH 8.0, 1 mM EDTA, 167 mM NaCl, 1% Triton X-100 and 0.01% SDS). The supernatant was then incubated for 1 h at 4 °C with 50 μ l protein G magnetic beads that had been pre-incubated with 5 μ g of control rabbit IgG and then incubated overnight at 4 °C with 50 μ l protein G magnetic beads that had been pre-incubated with an anti-Brd4 antibody (Bethyl Laboratories). Beads were then washed three times with 20 mM Tris-HCl (pH 8.0), 150 mM NaCl, 2 mM EDTA, 0.1% SDS and 1% Triton X-100, once with 50 mM Tris, 500 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.1% SDS and 1% Triton X-100, once with 20 mM Tris, 250 mM lithium chloride, 1 mM EDTA, 0.5% sodium deoxycholate and 0.5% NP-40, and once with TE. Bound complexes were eluted from the beads using 0.1 M sodium bicarbonate with 1% SDS by heating at 65 °C for 30 min with continuous shaking, and crosslinking was reversed by overnight incubation at 65 °C. Input DNA from the sonication step was also treated for crosslink reversal.
Purified ChIP DNA was used for qRT-PCR (see Supplementary Table 3 for primers) or used to prepare Illumina multiplexed sequencing libraries. For both Nanog and Brd4 ChIP-qPCR, values shown are from technical replicates (n = 3) of a single immunoprecipitation. Each immunoprecipitation was performed at least two independent times. For both Brd4 and Med1 ChIP-seq, libraries for Illumina sequencing were prepared using Nextflex Barcoding Adapters (Bioo Scientific) and a KAPA library amplification kit according to the manufacturer's instructions. Samples were sequenced using Illumina HiSeq generating 50-bp paired-end reads. Reads were trimmed for quality and Illumina adapter sequences using 'trim_galore' before aligning to mouse assembly mm9 with bowtie2 using the default parameters. Aligned reads with the same start site and orientation were removed using the Picard tool MarkDuplicates (http://broadinstitute.github.io/picard/). Density profiles were created by extending each read to the average library fragment size and then computing the density using the BEDTools suite (http://bedtools. readthedocs.io). Enriched regions were discovered using MACS 1.4 with default parameters and scored against matched input libraries. All genome browser tracks and read density tables were normalized to sequencing depth. Promoter-based comparisons used the normalized read density within ± 2 kb of the transcription start site, whereas non-promoter signals were also normalized to peak length. Dynamic regions between two conditions were scored using MACS with the second ChIP library replacing the input, and only sites with an absolute fold change greater than two were scored as a gain/loss. For gene-based analyses, all peaks within 30 kb of a gene were assigned to the relevant gene (or genes). For ChIP-seq scatter plots, read density was calculated using featureCounts (http://subread.sourceforge.net/) in paired-end mode with a minimum quality threshold of ten. Read density was subsequently normalized to a sequencing depth of 10 million mapped reads.
ATAC-seq.
ESCs were seeded at 150,000 cells per well of a six-well plate and treated the following day with DMSO or 500 nM JQ1. Cells were passaged into fresh six-well plates after 24 h of treatment and harvested after a total of 72 h of treatment. Duplicate samples from replicate wells were prepped for each condition. For each sample, 100,000 cells were harvested and washed with ATAC buffer (Tris 10 mM pH 7.4, 10 mM NaCl and 3 mM MgCl 2 ). Samples were spun at 1,000g for 5 min at 4 °C. Pellets were resuspended in 50 μ l of ATAC lysis buffer (Tris 10 mM pH 7.4, 10 mM NaCl, 3 mM MgCl 2 and 0.1% NP-40 or Igepal-Ca630). Nuclei were collected after centrifugation at 1,000g for 10 min at 4 °C. After discarding supernatant, tagmentation was performed at 37 °C for 30 min (FC-121-1030, Illumina Nextera DNA Sample Preparation Kit). DNA was collected using Qiaquick PCR purification columns according to the manufacturer's instructions and eluted in 10 μ l elution buffer (10 mM Tris, pH 8). Eluted DNA was mixed with NEBNext Q5 Hot Start HiFi PCR Master Mix (M0543L, NEB) and primer mix (Nextera). DNA was amplified by PCR (65 °C, 5 min; 98 °C, 30 s; 98 °C, 10 s, 65 °C, 1 min 15 s (12× )) and purified using AMPure XP beads (ratio of 1.5/1). Library quality control was performed using a Quant-iT Picogreen dsDNA Assay Kit (P7589, Life Technologies) and the median fragment size using an Agilent D1000 screentape (5067-5582). Samples were pooled for multiplexing and sequenced using paired-end sequencing technology on the Illumina NextSeq 500 platform. Sequencing and data processing were identical to ChIP-seq, except in the density profile creation step, in which reads were not extended. Enriched regions were discovered using MACS and scored against matched input libraries (fold change > 2 and P < 0.005), and peaks within 500 bp were merged. All genome browser tracks and read density tables were normalized to sequencing depth. For gene-based analyses, each peak was assigned to the most proximal transcription start site based on the linear genomic distance. K-means clustering of ATACseq data was performed on all peaks whose accessibility was maintained and/or increased with Nanog overexpression and whose accessibility also decreased with JQ1 treatment in control cells. Dynamic peaks were annotated with Homer v4.5 (http://homer.salk.edu/homer/ngs/annotation.html) using a distance threshold of 50 kb. Unless otherwise noted, values shown are the average of duplicate samples.
Gene set enrichment analysis. Gene set enrichment analysis (GSEA) 62 was performed using ranked lists or normalized read counts. Mueller PluriNet and Wong ESC Core gene lists are found in the MSigDB 62 . GSEAPreranked version 4 was used with default parameters, and data were exported and graphed in GraphPad Prism version 7.
Western blotting. Protein lysates were extracted in RIPA buffer (Cell Signaling) or Laemmli buffer, separated by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad) or Polyvinylidene difluoride (PVDF) membranes (Millipore). Membranes were blocked in 5% milk in Tris-buffered saline with 0.1% Tween-20 (TBST) and incubated at 4 °C with primary antibodies overnight. After TBST washes the next day, membranes were incubated with horseradish peroxidase-conjugated secondary antibodies for 1 h, incubated with ECL (Pierce or GE Healthcare) and imaged using Ecomax X-Ray Film Processor (Protec) or FluorChem M System (ProteinSimple). Antibodies used (at 1:1,000 unless otherwise noted) were pSTAT3 (9138, Cell Signaling Technologies), STAT3 (9139, Cell Signaling Technologies) pERK (4377, Cell Signaling Technologies), ERK (9102, Cell Signaling Technologies), tubulin (1:10,000, T9026, Sigma), Brd4 (1:2,000, A301-985A100, Bethyl Laboratories), nucleolin (1:5,000, ab22758, Abcam), Nanog (14-5761-80, Ebioscience) and actin (1:20,000, A3854, Sigma).
Growth curves.
ESCs were seeded at a concentration of 30,000-40,000 cells per well of a 12-well plate. The next day, three wells of each line were counted to determine the starting cell number. The remaining cells were washed with PBS and put in fresh medium with indicated inhibitors or relevant vehicle control. Cells were counted on the indicated days thereafter using a Beckman Multisizer 3 with a cell volume gate of 400-10,000 fL. Medium was changed every day. For growth curves using cells expressing shRNA, cells were pre-treated with or without doxycycline for 48 h prior to seeding for curve and subsequent cell counts were normalized to seeding density. All curves were performed at least two independent times.
Quantification of gene expression. RNA was isolated from six-well plates using TRIzol (Invitrogen) according to the manufacturer's instructions and 200 ng RNA was used for cDNA synthesis using iScript (Bio-Rad). Quantitative real-time PCR analysis was performed in technical triplicate using QuantStudio 7 Flex (Applied Biosystems) with Power SYBR Green (Life Technologies). All data were generated using cDNA from triplicate wells for each condition. Actin was used as an endogenous control for all experiments except Supplementary Fig. 7i , for which 18S was used. Primers used for qRT-PCR are shown in Supplementary Table 3 . For RNA sequencing (RNA-seq), RNA was isolated from ESCs using TRIzol and then samples were prepared as instructed using the TruSeq RNA Sample Preparation Kit v2 (Illumina) in accordance with the manufacturer's instructions. RNA-seq samples were sequenced using Illumina NextSeq 500, generating 75-bp single-end reads. Fastq files were aligned to genome build mm9 using TopHat with default parameters. Aligned features were counted with htseq-count, and differential expression was determined using the edgeR package in Bioconductor as previously described 63 .
Colony formation assays. Cells were seeded at the indicated density in six-well plates. For experiments with continuous JQ1, 200 cells were seeded per well. The next day, cells were washed with PBS and put into fresh medium with DMSO or 500 nM JQ1 and medium was changed daily thereafter. For experiments with acute JQ1 treatment, 200 cells were seeded per well and medium was refreshed every 2-3 days. Forty-eight hours prior to fixation, cells were given fresh medium containing DMSO or 500 nM JQ1. For experiments with FACS-sorted cells transduced with GFP-Cas9 and the indicated gRNAs, 10,000 GFP-positive cells were seeded in duplicate. For experiments with clonal CRISPR-Cas9-edited cell lines, ESCs from each individual clone were cultured in S/L or S/L + 2i for 48 h and then seeded at a density of 200 cells per well. Medium was refreshed every 2-3 days. For all experiments, 7 days after initial seeding, wells were fixed with citrate, acetone and 3% formaldehyde for 30 s and stained using the Leukocyte Alkaline Phosphatase Kit (Sigma) according to the manufacturer's instructions. For colony formation assays in S/L medium, colonies were scored manually in a blinded manner. For colony formation assays in S/L + 2i medium, AP+ colonies were scored automatically using ImageJ (NIH). Briefly, images of each well were binarized using the MaxEntropy function, and particles > 12 pixels with a circularity of 0.5-1.0 were counted.
Chimaera assays. Mice and embryos.
Animal experiments comply with all relevant ethical regulations. All animal experiments were carried out according to the protocol approved by the Institutional Animal Care and Use Committee of Weill Cornell Medical College (protocol number: 2014-0061). ICR female mice were purchased from Taconic Farms. Females were superovulated at 6-8 weeks with 10 IU PMSG (pregnant mare serum gonadotrophin, Sigma-Aldrich) and 10 IU hCG (human chorionic gonadotrophin, Sigma-Aldrich) at intervals of 48 h. The females were mated individually to males and checked for the presence of a vaginal plug the following morning. Plugged females were killed at 1.5 days after hCG injection for collection of 2-cell embryos. These embryos were flushed from the oviducts with KSOM + amino acids (specialty media) and cultured in KSOM for 2.5 days in vitro at 37 °C under 5% CO 2 in air to the blastocyst stage.
Blastocyst injection and embryo transfer. ESCs were treated with DMSO or JQ1 as described above and kept on ice until injection. A flat-tip microinjection pipette was used for ESC injection using the Piezo Micromanipulator (Prime Tech) to break the embryos. ESCs were picked up in the end of the injection pipette and 15-20 ESCs were injected into each blastocyst. The injection pipette was also used to collect ESCs as a clump and to place them close to the inner cell mass of the blastocyst. The injected blastocysts were kept in KSOM + amino acids until embryo transfer. Ten injected blastocysts were transferred into each uterine horn of 2.5 d.p.c. pseudopregnant ICR females. 64 were seeded at a concentration of 40,000 cells per well of a 12-well plate. The next day, cells were washed with PBS and put in fresh medium with indicated inhibitors or relevant vehicle control. Twenty-four hours later, cells were trypsinized and resuspended in PBS plus 0.5% BSA and evaluated for GFP expression on a LSRFortessa machine (Beckman Dickinson). Analysis of GFP mean fluorescence intensity was performed using FlowJo v9.0. All experiments were performed at least two independent times. 
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Data collection
No software was used for data collection.
Data analysis
Statistical tests were performed using GraphPad Prism v7.0a (for all bar graphs). For GSEA studies, statistical results are included as part of the default paramaters of the GenePattern GSEAPreranked v6.0.10 module. ImageJ v 1.43u was used for colony formation assays.
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Sample preparation minutes at 37C. They were centrifuged, washed 3x in FACS buffer and resuspended in FACS buffer containing DAPI. They were analyzed on a flow cytometer within 30 minutes. Instrument BD LSR Fortessa (for analysis), BD FACSAria III (for sorting)
Software
FACSDiva was used for data acquisition. FlowJo 9.0 was used for data analysis.
Cell population abundance Clonal cell lines were used for all experiments.
Gating strategy
The gating strategy was initially FSC-A by SSC-A, followed by doublet exclusion using FSC-H and SSC-H, and finally DAPI exclusion using FSC-A by DAPI-A in which DAPI-negative cells were in the lowest quartile of DAPI-A expression. In all cases, DAPI positive cells retained 100x more DAPI than negative cells.
Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.
